commercialgrad
rhmbl
provid
enzon
pharmaceut
human
mbl
concentr
complement
cleavag
activ
measur
describ
elsewher
pharmacokinet
rhmbl
data
evalu
use
noncompartment
model
winnonlin
profession
edit
version
pharsight
area
curv
zero
infin
valu
calcul
use
linear
trapezoid
method
use
valid
lethal
ebola
zair
mous
model
develop
us
armi
medic
research
institut
infecti
diseas
usamriid
doubl
plaquepurifi
mouseadapt
ebola
isol
gh
viru
inocul
intraperiton
ip
pfu
produc
uniformli
lethal
diseas
mice
use
biosafeti
facil
research
conduct
complianc
anim
welfar
act
feder
regul
fulli
accredit
facil
assess
effect
rhmbl
viru
lethal
treat
ebola
mice
ip
either
mgkg
mgkg
rhmbl
twice
daili
hour
apart
day
day
viru
exposur
mice
treat
expos
pfu
mouseadapt
ebola
zair
either
hour
hour
first
dose
rhmbl
indic
figur
mice
assess
daili
chang
physic
appear
weight
viremia
assess
revers
transcriptionpolymeras
chain
reaction
rtpcr
plaqu
assay
describ
elsewher
viru
antibodi
measur
use
standard
enzymelink
immunosorb
assay
elisa
standard
blood
count
evalu
coulter
diff
beckman
coulter
analysi
flow
cytometri
spleen
ground
singl
cell
suspens
bd
medimachin
tissu
grinder
incub
fc
block
bd
cell
wash
incub
antibodi
fitc
bd
bd
percp
ebio
pe
ebio
apc
bd
bd
cell
wash
pb
fix
bd
cytofix
data
immedi
acquir
bd
facscantoii
analyz
flowjo
version
bioplex
mous
cytokin
panel
assay
biorad
use
measur
multipl
cytokin
chemokin
growth
factor
serum
tissu
supernat
accord
manufactur
instruct
mice
surviv
initi
infect
test
ebolaspecif
serolog
respons
day
rechalleng
viru
dose
without
treatment
antibodi
titer
retest
day
later
previous
found
rhmbl
bound
ebola
zair
marburg
musok
envelop
gp
rhmbl
effect
block
ebola
gp
interact
dcsign
hiv
particl
lack
pseudotyp
ebola
marburg
gp
neutral
lectin
complement
pathway
develop
vivo
test
rhmbl
effect
determin
ngml
rhmbl
minimum
concentr
need
inhibit
infect
cell
use
ebola
gp
pseudotyp
lentivir
particl
inhibit
infect
vero
cell
use
recombin
ebola
zair
viru
mayinga
strain
egfp
data
shown
previous
found
singl
intraperiton
dose
rhmbl
reconstitut
lectin
complement
pathway
mblknockout
mice
compar
pharmacokinet
paramet
tabl
singl
reconstitut
dose
mgkg
higher
singl
intraperiton
dose
mgkg
identifi
potenti
supraphysiolog
dose
test
model
infect
averag
maximum
serum
concentr
cmax
dose
exceed
minimum
concentr
mbl
inhibit
infect
vitro
least
averag
ratio
maximum
baselin
complement
compon
cleavag
activ
rhmbl
dose
dose
intraperiton
administr
pfu
nativ
ebola
zair
viru
uniformli
fatal
mice
treatment
rhmbl
per
dose
everi
hour
fail
protect
mice
viru
inoculum
therefor
increas
rhmbl
administ
everi
hour
day
start
either
hour
hour
ebola
viru
challeng
figur
treatment
start
hour
viru
infect
supraphysiolog
dose
increas
surviv
mice
sever
trial
figur
start
treatment
hour
viral
infect
compar
surviv
wildtyp
complement
compon
mice
inhibitori
effect
mbl
ebola
viru
mediat
complement
cell
cultur
saw
increas
surviv
rhmbltreat
mice
surviv
depend
intact
complement
pathway
sinc
mice
surviv
figur
inocul
mice
show
sign
infect
accord
standard
observ
score
weight
loss
surviv
mice
detect
ebola
antibodi
day
infect
data
shown
monitor
effect
treatment
start
hour
infect
varieti
laboratori
indic
mean
white
blood
cell
count
cellsml
mbltreat
mice
n
compar
cellsml
day
infect
surviv
shamtreat
mice
n
averag
lymphocyt
count
also
higher
mbltreat
mice
compar
control
cellsml
vs
cellsml
respect
similar
trend
seen
platelet
count
averag
cellsml
treatment
group
cellsml
control
differ
statist
signific
platelet
count
day
cellsml
vs
cellsml
p
figur
separ
experi
spleen
harvest
day
infect
shamtreat
mbltreat
mice
constitu
cell
popul
assay
flow
cytometri
number
splenic
cell
b
lymphocyt
granulocyt
higher
mbltreat
mice
vs
p
vs
p
respect
rna
viral
load
determin
rtpcr
blood
liver
spleen
day
infect
similar
sham
rhmbltreat
mice
p
viru
titer
blood
gener
lower
day
rhmbltreat
mice
determin
plaqu
assay
p
figur
cytokin
chemokin
test
serum
liver
spleen
day
inocul
lower
valu
fluoresc
intens
unit
interleukin
il
vs
p
vs
p
vs
p
vs
p
vs
p
found
liver
homogen
rhmbltreat
mice
figur
test
protect
immun
seroposit
mice
surviv
initi
infect
rechalleng
nativ
ebola
viru
day
initi
infect
noteworthi
mbltreat
survivor
also
surviv
second
viral
challeng
similar
higher
immunoglobulin
g
antibodi
titer
seen
day
second
challeng
viru
figur
studi
support
grant
ev
nation
institut
health
nih
ev
addit
support
nih
grant
ggo
addit
support
defens
threat
reduct
agenc
medic
biolog
defens
research
program
therapeut
research
program
kt
receiv
addit
support
nih
grant
